ArticleActa neurochirurgica2026
Pressor use and its impact on outcomes in aneurysmal subarachnoid hemorrhage patients with takotsubo cardiomyopathy: a quantitative analysis.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTakotsubo cardiomyopathy (TCM) is induced by catecholamine-induced cardiotoxicity. Though uncommon after aneurysmal subarachnoid hemorrhage (aSAH), TCM increases patient morbidity and mortality in an already-devastating disease process. The fear of worsening shock in TCM with blood pressure augmentation in patients with symptomatic vasospasm poses a dilemma for clinicians. This study aims to assess the relationship between vasopressor use after aSAH and TCM.
methodA multi-institutional chart review evaluated aSAH adult patients treated from 2015 to 2021. TCM diagnosis was the primary endpoint upon which the group was stratified. Baseline demographics, clinical presentation, aneurysm characteristics, adverse events, short-term outcomes, treatment variables, and vasopressor usage in average daily norepinephrine equivalent were collected.
results311 patients were included; 13 (4.2%) had a TCM diagnosis. Median TCM diagnosis day was post-bleed day 4 (IQR 2-5). High-grade rupture (Hunt Hess score ≥ 3) was associated with TCM (p = 0.010). Vasopressor use after aneurysm securement was associated with TCM (p < 0.001). Vasospasm requiring multiple endovascular treatments, myocardial infarction, prolonged intubation, and general poor outcomes were significantly more prevalent in the TCM group on univariate analysis. On multivariate analysis, vasopressor use was not significantly associated with TCM (OR 4.275, CI 0.295-61.952, p = 0.287).
conclusionIn this sample of aSAH patients, a majority of TCM diagnoses were made within 5 days post-bleed. Most TCM patients were diagnosed prior to vasopressor initiation. Vasopressor use was not predictive of TCM in aSAH patients on multivariate analysis, suggesting its use is not a factor, though further study is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.